The p38 MAPK Pathway Is Required for Cell Growth Inhibition of Human Breast Cancer Cells in Response to Activin
Open Access
- 1 May 2001
- journal article
- Published by Elsevier BV in Online Journal of Public Health Informatics
- Vol. 276 (21), 18430-18436
- https://doi.org/10.1074/jbc.m010768200
Abstract
No abstract availableThis publication has 49 references indexed in Scilit:
- Roles of Pathway-Specific and Inhibitory Smads in Activin Receptor SignalingMolecular Endocrinology, 1999
- Human Smad3 and Smad4 Are Sequence-Specific Transcription ActivatorsMolecular Cell, 1998
- TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4The EMBO Journal, 1997
- MADR2 Is a Substrate of the TGFβ Receptor and Its Phosphorylation Is Required for Nuclear Accumulation and SignalingCell, 1996
- Regulation of transforming growth factor β- and activin-induced transcription by mammalian Mad proteinsProceedings of the National Academy of Sciences of the United States of America, 1996
- Partnership between DPC4 and SMAD proteins in TGF-β signalling pathwaysNature, 1996
- Receptor-associated Mad homologues synergize as effectors of the TGF-β responseNature, 1996
- A novel mesoderm inducer, Madr2, functions in the activin signal transduction pathway.Genes & Development, 1996
- Activation of Signalling by the Activin Receptor ComplexMolecular and Cellular Biology, 1996
- Mechanism of activation of the TGF-β receptorNature, 1994